Regeneron announced the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received EUA from the FDA. Read more...
Pfizer and BioNTech announced they will submit a request to the FDA for EUA of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. Read more…
Novartis has entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of ARDS, including that associated with COVID-19. Read more…
Sagent has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate for the treatment of COVID-19 in high-risk outpatients and has begun enrolling patients. Read more…
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.